Stanford Graduate School of Business (USA)
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74
-
Part IV: Uber in Seoul
Callander, Steven; Orleans, Amadeus; Conn, JeffCase SGSB-P81D-EEconomicsThis case recounts Uber’s experience in four cities at different points in time. This approach offers a way to examine Uber’s strategy for market entry and evaluate the performance of that strategy in these four cities, as well as elsewhere in the world. The cases included here help frame the discussion on the future of Uber’s expansion, and extract lessons for how a firm can successfully navigate the beyond-market business environment.Starting at €8.20
-
Golden Gate Ventures: Fundraise Decisions
Antoni, Federico; Conn, JeffCase SGSB-E769-EEntrepreneurshipThis case explores the founding story and growth trajectory of Singapore-based venture capital firm Golden Gate Ventures as it grows its operations and asset base alongside the rapidly growing venture ecosystem in Southeast Asia. It also analyzes the core venture capital fund business model and evaluates a consequential decision regarding the firm’s upcoming fundraise.Starting at €8.20
-
Lloyds Banking Group: Digital Transformation
Feinberg, Yossi; Conn, JeffCase SGSB-SM329-EStrategyThis case describes the transformation of the UK’s oldest financial services franchise from a product-aligned and brick-and-mortar traditional banking institution to a customer-aligned and digital-first technology organization. The case parallels Lloyds’ business transformation with the growth of its digital-focused Transformation division – which commenced as a small hundred-person task force and ultimately grew to comprise one third of the bank...Starting at €8.20
-
Invitrogen/Life Technologies (C): The "Best Owner" of the Asset
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209C-EStrategyThis short case discusses the process of Life Technologies’ acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.Starting at €5.74
-
D.Light: Selling Solar to the Poor
Jesper Sorensen, Michael Kennedy, Gina JoraschCase SGSB-IDE03-EEconomicsD.light is one of the leading manufacturers of solar powered lighting technology specifically designed for use by the world’s poorest, bottom of the pyramid customers. Having sold over 7 million lights since 2007, the company has been relatively successful. However, sales to the very poorest customers have failed to reach penetration levels desired by management, and the company is currently struggling with an array of marketing techniques and ...Starting at €8.20